Dimensional Fund Advisors
RPRX icon

Dimensional Fund Advisors’s Royalty Pharma RPRX Stock Holding History

Dimensional Fund Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.3M Sell
1,056,354
-22,011
-2% -$1.15M 0.01% 1499
2026
Q1 		$51.7M Sell
1,078,365
-1,233,763
-53% -$54M 0.01% 1483
2025
Q4 		$89.4M Buy
2,312,128
+211,638
+10% +$8.07M 0.02% 1156
2025
Q3 		$74.1M Buy
2,100,490
+205,498
+11% +$7.44M 0.02% 1287
2025
Q2 		$68.3M Buy
1,894,992
+179,605
+10% +$5.95M 0.02% 1306
2025
Q1 		$53.4M Buy
1,715,387
+34,852
+2% +$1.1M 0.01% 1435
2024
Q4 		$42.9M Buy
1,680,535
+580,787
+53% +$15.4M 0.01% 1601
2024
Q3 		$31.1M Buy
1,099,748
+312,491
+40% +$8.66M 0.01% 1778
2024
Q2 		$20.8M Buy
787,257
+139,761
+22% +$3.87M 0.01% 1936
2024
Q1 		$19.7M Buy
647,496
+18,927
+3% +$558K 0.01% 1995
2023
Q4 		$17.7M Buy
628,569
+126,705
+25% +$3.48M 0.01% 2048
2023
Q3 		$13.6M Buy
501,864
+99,317
+25% +$2.95M ﹤0.01% 2102
2023
Q2 		$12.4M Buy
402,547
+12,588
+3% +$426K ﹤0.01% 2163
2023
Q1 		$14.1M Buy
+389,959
New +$14.5M ﹤0.01% 2075
2022
Q3 		$13.5M Buy
335,439
+42,479
+14% +$1.81M 0.01% 2033
2022
Q2 		$12.3M Buy
292,960
+8,019
+3% +$329K ﹤0.01% 2108
2022
Q1 		$11.1M Buy
284,941
+54,740
+24% +$2.15M ﹤0.01% 2246
2021
Q4 		$9.17M Buy
230,201
+69,686
+43% +$2.71M ﹤0.01% 2340
2021
Q3 		$5.8M Buy
160,515
+151,369
+1,655% +$5.88M ﹤0.01% 2544
2021
Q2 		$375K Sell
9,146
-295
-3% -$12.5K ﹤0.01% 3217
2021
Q1 		$413K Buy
+9,441
New +$448K ﹤0.01% 3176

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors's RPRX Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its Royalty Pharma (RPRX) stake by 2% in Q2 2026, selling an estimated $1.15M and leaving 1,056,354 shares worth $59.3M. The position accounts for 0.01% of the portfolio, ranked #1499.

Dimensional Fund Advisors first reported a position in RPRX in Q1 2021 and has held it in 21 quarters since. The position peaked at $89.4M in Q4 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Dimensional Fund Advisors held 1,056,354 shares of Royalty Pharma worth $59.3M as of Q2 2026.
  • Dimensional Fund Advisors sold 22,011 Royalty Pharma shares in Q2 2026, an estimated $1.15M.
  • Royalty Pharma made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1499 holding.
  • Dimensional Fund Advisors first reported a position in Royalty Pharma in Q1 2021 and has held it in 21 quarters since.
  • Dimensional Fund Advisors's Royalty Pharma position peaked at $89.4M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.